Albert J. Bonebrake

788 total citations
23 papers, 531 citations indexed

About

Albert J. Bonebrake is a scholar working on Reproductive Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Albert J. Bonebrake has authored 23 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Reproductive Medicine, 12 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Albert J. Bonebrake's work include Ovarian cancer diagnosis and treatment (14 papers), Endometrial and Cervical Cancer Treatments (7 papers) and Intraperitoneal and Appendiceal Malignancies (5 papers). Albert J. Bonebrake is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Endometrial and Cervical Cancer Treatments (7 papers) and Intraperitoneal and Appendiceal Malignancies (5 papers). Albert J. Bonebrake collaborates with scholars based in United States, Australia and Canada. Albert J. Bonebrake's co-authors include James Kauderer, John A. Blessing, David S. Alberts, Joan L. Walker, Carol Aghajanian, Angeles Alvarez Secord, Bradley J. Monk, John O. Schorge, Diane C. Bodurka and Yi-Chun Lee and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Gynecologic Oncology.

In The Last Decade

Albert J. Bonebrake

23 papers receiving 524 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Albert J. Bonebrake United States 14 245 234 199 106 98 23 531
Richard D. Drake United States 15 159 0.6× 341 1.5× 336 1.7× 155 1.5× 109 1.1× 20 716
William E. Richards United States 8 126 0.5× 345 1.5× 330 1.7× 57 0.5× 67 0.7× 14 547
Stelios Fotiou Greece 17 117 0.5× 311 1.3× 286 1.4× 107 1.0× 88 0.9× 51 689
Valentina Zanfagnin United States 12 182 0.7× 182 0.8× 223 1.1× 76 0.7× 47 0.5× 24 470
Kimihiko Ito Japan 13 107 0.4× 147 0.6× 231 1.2× 135 1.3× 51 0.5× 50 436
Fumitoshi Terauchi Japan 10 211 0.9× 262 1.1× 511 2.6× 142 1.3× 70 0.7× 31 716
Karen Lu United States 6 112 0.5× 251 1.1× 228 1.1× 94 0.9× 28 0.3× 15 480
Mojca Persic United Kingdom 6 147 0.6× 64 0.3× 167 0.8× 103 1.0× 70 0.7× 12 345
Jaime Coronel Mexico 13 96 0.4× 191 0.8× 83 0.4× 194 1.8× 65 0.7× 22 465
Daniel Donato United States 13 140 0.6× 271 1.2× 172 0.9× 102 1.0× 67 0.7× 29 532

Countries citing papers authored by Albert J. Bonebrake

Since Specialization
Citations

This map shows the geographic impact of Albert J. Bonebrake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert J. Bonebrake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert J. Bonebrake more than expected).

Fields of papers citing papers by Albert J. Bonebrake

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert J. Bonebrake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert J. Bonebrake. The network helps show where Albert J. Bonebrake may publish in the future.

Co-authorship network of co-authors of Albert J. Bonebrake

This figure shows the co-authorship network connecting the top 25 collaborators of Albert J. Bonebrake. A scholar is included among the top collaborators of Albert J. Bonebrake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert J. Bonebrake. Albert J. Bonebrake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Short, Rick Jay, et al.. (2022). Yolk sac tumor presenting as a colonic mass in a post-menopausal woman: A case report. Gynecologic Oncology Reports. 42. 101038–101038. 1 indexed citations
3.
4.
Farley, John, William E. Brady, David M. O’Malley, et al.. (2022). A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial. Gynecologic Oncology. 167(3). 423–428. 15 indexed citations
5.
Carter, Jeanne, Helen Huang, Jane M. Armer, et al.. (2020). GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecologic Oncology. 160(1). 244–251. 45 indexed citations
6.
Carter, Jeanne, Helen Huang, Jane M. Armer, et al.. (2019). GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE). Gynecologic Oncology. 155(3). 452–460. 36 indexed citations
7.
Carlson, Jay W., James Kauderer, Alan D. Hutson, et al.. (2019). GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecologic Oncology. 156(2). 467–474. 73 indexed citations
8.
9.
10.
Kauderer, James, Alan D. Hutson, Sandra Nolte, et al.. (2018). GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecologic Oncology. 149. 6–7. 8 indexed citations
11.
Chan, John K., Wei Deng, Robert V. Higgins, et al.. (2017). A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 146(3). 554–559. 16 indexed citations
12.
Chan, John K., Wei Deng, Robert V. Higgins, et al.. (2015). A phases II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.. Journal of Clinical Oncology. 33(15_suppl). e16599–e16599. 2 indexed citations
13.
14.
Schilder, Russell J., Michael W. Sill, Heather A. Lankes, et al.. (2013). A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study. Gynecologic Oncology. 129(1). 86–91. 22 indexed citations
15.
Alberts, David S., John A. Blessing, Lisa M. Landrum, et al.. (2012). Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecologic Oncology. 127(3). 451–455. 51 indexed citations
16.
Kunos, Charles A., Tomas Radivoyevitch, Fadi W. Abdul‐Karim, et al.. (2012). Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. Journal of Translational Medicine. 10(1). 79–79. 22 indexed citations
17.
Covens, Allan, Virginia L. Filiaci, Deborah J. Gersell, et al.. (2010). Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology. 120(2). 185–188. 51 indexed citations
18.
Monk, Bradley J., Michael W. Sill, Parviz Hanjani, et al.. (2010). Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group. Gynecologic Oncology. 120(3). 459–463. 13 indexed citations
19.
Monk, B.J., Michael W. Sill, Joan L. Walker, et al.. (2010). Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG).. Journal of Clinical Oncology. 28(15_suppl). 5046–5046. 2 indexed citations
20.
Miller, David S., John A. Blessing, Diane C. Bodurka, Albert J. Bonebrake, & John O. Schorge. (2008). Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecologic Oncology. 110(1). 65–70. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard D. Drake Breakdown of academic impact, for papers by William E. Richards Breakdown of academic impact, for papers by Stelios Fotiou Breakdown of academic impact, for papers by Valentina Zanfagnin Breakdown of academic impact, for papers by Kimihiko Ito Breakdown of academic impact, for papers by Fumitoshi Terauchi Breakdown of academic impact, for papers by Karen Lu Breakdown of academic impact, for papers by Mojca Persic Breakdown of academic impact, for papers by Jaime Coronel Breakdown of academic impact, for papers by Daniel Donato
Rankless by CCL
2026